Sector News

Shire will cut U.S. locations and move HQ in consolidation push

July 5, 2017
Life sciences

Shire has decided to concentrate its U.S. operations into two main sites in Massachusetts—Cambridge and Lexington—in a move that will probably lead to the closure of some sites.

The Ireland-headquartered group employs more than 3,000 people in the state but stressed that despite the consolidation plans, it does not expect any significant reduction in overall headcount. In fact, some R&D staffers will be moved to Massachusetts from Europe and the company is expecting to make plenty of new hires in the coming years.

When the process is completed, its rare disease research and U.S. commercial operations will be based at a site in Kendall Square, Cambridge, that was formerly operated by Sanofi Genzyme and was leased last year, along with an adjacent site that put together form a 550,000-square-foot campus.

Meanwhile, Lexington—the company’s current U.S. HQ—will be the location for manufacturing of biologic drugs and the development and production of delivery systems, including digitally connected devices.

Shire is now the state’s second-largest biopharma employer, according to a Boston Globe article (sub. req.), but according to the company’s CEO Flemming Ornskov it has “a bit of a fragmented structure” there with staff “spread out in many locations” including units at Alewife, Milford, Burlington and North Reading.

Not all of the company’s Massachusetts employees are happy with the news, however, with some concerned that they will face big problems commuting into the increasingly congested Kendall Square area.

The move comes in the midst of a big transformation for Shire, which acquired both Dyax and Baxalta last year and left it with a huge task in refining its commercial structures, ushering a dramatically increased pipeline of products to market and advancing a broader R&D base with around 40 drugs in clinical development.

Shire has already started to streamline its locations in the wake of the takeovers, and is currently taking a good look at its manufacturing network, where it currently has 17 sites in seven countries and employs around 14,000 people.

Ornskov will be directly overseeing the changes—that are due to complete by mid-2019—for the time being following the departure of former R&D chief Phil Vickers, who has said he intends to step down from the position.

By Phil Taylor

Source: Fierce Biotech

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend